Developments of the fluoropyrimidines as inhibitors of thymidylate synthetase: pharmacologic and clinical aspects.
Machover
D
D
Service d'Oncologie Medicale, Hôpital Tenon, Paris, France.
D000818:Animals; D000970:Antineoplastic Agents; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D004357:Drug Synergism; D005467:Floxuridine / Q000627:therapeutic use; D005472:Fluorouracil / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D006801:Humans; D002955:Leucovorin / Q000627:therapeutic use; D009944:Organoplatinum Compounds / Q000627:therapeutic use; D011355:Prodrugs; D011743:Pyrimidines / Q000627:therapeutic use*; D013940:Thymidylate Synthase / Q000037:antagonists & inhibitors*
D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D011355:Prodrugs; D011743:Pyrimidines; D005467:Floxuridine; C055423:didimethylsulfoxide dichloroplatinum(II); C029269:5-fluoropyrimidine; D013940:Thymidylate Synthase; D002955:Leucovorin; D005472:Fluorouracil